The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Extrahepatic Platelet-Derived Growth Factor-β, Delivered by Platelets, Promotes Activation of Hepatic Stellate Cells and Biliary Fibrosis in Mice
Open accessAbstract
Background & aims Platelet-derived growth factor-β (PDGFB) is a mitogen for hepatic stellate cells (HSCs). We studied the cellular sources of PDGFB and the effects of a high-affinity monoclonal antibody against PDGFB (MOR8457) in mouse models of biliary fibrosis.Methods Cellular sources of PDGFB were identified using quantitative reverse-transcription polymerase chain reaction, biochemical, and immunohistologic methods. Mice with advanced biliary fibrosis, MDR2(Abcb4)-null mice, and C57Bl/6 (control) mice were placed on 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-supplemented diets and were given weekly intraperitoneal injections of MOR8457. Platelets were depleted from MDR2-null mice by injection of an antibody against CD41, or inhibited with diets containing low-dose aspirin. Liver tissues were collected and analyzed by quantitative reverse-transcription PCR and histologic and biochemical analyses.Results Levels of PDGFB protein, but not messenger RNA, were increased in fibrotic livers of MDR2-null mice, compared with control mice. Platelet clusters were detected in the hepatic endothelium, in close proximity to HSCs, and were identified as a source of PDGFB protein in MDR2-null mice. Levels of the PDGFB were increased in serum samples from patients with early stages of liver fibrosis of various etiologies (F1-2, n = 16; P < .05), compared with nonfibrotic liver tissue (F0, n = 12). Depletion of platelets from MDR2-null mice normalized hepatic levels of PDGFB within 48 hours, reducing levels of a marker of HSC activation (α-smooth muscle actin) and expression of genes that promote fibrosis. Diets supplemented with low-dose aspirin reduced circulating serum and hepatic levels of PDGFB and significantly reduced progression of fibrosis in MDR2-null mice over 1 year. MOR8457 produced a dose-dependent decrease in liver fibrosis in MDR2-null mice, reducing collagen deposition by 45% and expression of fibrosis-associated genes by 50%, compared with mice given a control antibody. In vitro, platelets activated freshly isolated HSCs (induction of α-smooth muscle actin and fibrosis-associated genes) via a PDGFB-dependent mechanism. MOR8457 also reduced liver fibrosis in mice placed on DDC-supplemented diets.Conclusions Platelets produce PDGFB to activate HSC and promote fibrosis in MDR2-null mice and mice on DDC-supplemented diets. Antiplatelet therapy or selective inhibition of PDGFB might reduce biliary fibrosis in patients with liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NASH, platelets interact with liver-resident KCs to promote the recruitment of CD8 T cells and NKT cells, depending on interactions between platelet-expressed GPIba and von Willebrand factor, thereby promoting disease.98”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,687
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., Rodríguez, L. A. G., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,223
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Primary Sclerosing Cholangitis
Lee, Y., & Kaplan, M. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321406 · Cited by 541
Primary sclerosing cholangitis
Lawson, A. (2014) · Radiopaedia.org · doi:10.53347/rid-26818 · Cited by 446
A New Xenobiotic-Induced Mouse Model of Sclerosing Cholangitis and Biliary Fibrosis
Fickert, P., Stöger, U., Fuchsbichler, A., Moustafa, T., Marschall, H., Weiglein, A. H., Tsybrovskyy, O., Jaeschke, H., Zatloukal, K., Denk, H., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061133 · Cited by 375
Sitia, G., Aiolfi, R., Lucia, P. D., Mainetti, M., Fiocchi, A., Mingozzi, F., Esposito, A., Ruggeri, Z., Chisari, F., Iannacone, M., et al. (2012) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1209182109 · Cited by 318
Popov, Y. V., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23123 · Cited by 297
Self-citationPopov, Y. V., Patsenker, E., Fickert, P., Trauner, M. A., & Schuppan, D. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.06.025 · Cited by 268
Self-citation
Cited by
Sorted by citations
Items 101–164 of 164
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH
Fraser, D. A., Harrison, S. A., & Schuppan, D. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159804 · Cited by 11
Self-citationWu, Z., Wu, Y.-C., Zhong, W., Zhong, Q., Rao, S., Yu, D., Luo, X., Qiu, F., Song, Z.-Y., Jin, D., et al. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11931 · Cited by 10
Jiang, Q., Mao, R., Wu, J., Chang, L., Zhu, H., Zhang, G., Ding, Z., & Zhang, J. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25641 · Cited by 10
Greimel, T., Jahnel, J., Pohl, S., Strini, T., Tischitz, M., Meier‐Allard, N., Holasek, S. J., Meinel, K., Aguiriano-Moser, V., Zobel, J., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00628-z · Cited by 10
Bitto, N., Ghigliazza, G., Lavorato, S., Caputo, C., & Mura, V. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030934 · Cited by 11
Siler, S. Q. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03295-x · Cited by 11
Boiling histotripsy exhibits anti-fibrotic effects in animal models of liver fibrosis
Joung, C., Heo, J., Pahk, K. J., & Pahk, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-66078-x · Cited by 9
Zhang, Z., Wu, J., Wang, J., Chen, Y., Yao, R., Zhu, L., Li, Y. G., Zhang, S., Pan, Y., Cao, F., et al. (2025) · QJM · doi:10.1093/qjmed/hcaf215 · Cited by 9
Kabra, H., Walimbe, T., Stuart, K., Indey, C., Jalgaonkar, S. P., Ikwa, E., Skurnac, T., Chen, J., Woolley, A. J., Snead, N. M., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120538 · Cited by 9
Xiang, Q., Tao, J., Li, J., Tian, R.-B., & Li, X.-H. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221125683 · Cited by 8
Ali, R., Moon, M. S., Townsend, E. C., Hill, K., Zhang, G. Y., Bradshaw, A., Guan, H., Hamilton, D., Kleiner, D. E., Auh, S., et al. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05760-x · Cited by 8
Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis
Queck, A., Thomas, D., Jansen, C., Schreiber, Y., Rüschenbaum, S., Praktiknjo, M., Schwarzkopf, K. M., Mücke, M. M., Schierwagen, R., Uschner, F. E., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222840 · Cited by 7
Huang, X., Khoong, Y., Han, C., Su, D., Ma, H., Gu, S., Li, Q., & Zan, T. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.694605 · Cited by 8
Meinel, K., Korak, F., Dusleag, M., Strini, T., Baumgartner, D., Burmas, A., Sallmon, H., Zieger, B., Schlagenhauf, A., & Köestenberger, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031240 · Cited by 6
Lambooij, J. M., Chavanelle, V., Vallier, M., van der Zande, H. J. P., Otero, Y. F., Otto, F., Schuurman, R., Joubioux, F. L., Maugard, T., Giera, M. A., et al. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00033-z · Cited by 6
Kexin, J. I. A., Zhi, M. A., ZHANG, Y., Kaihong, X. I. E., Jianan, L. I., Jianzhi, W. U., Jiaorong, Q. U., Fanghong, L. I., & Xiaojiaoyang, L. I. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60571-6 · Cited by 6
Lefeuvre, C., Roux, M., Blanchard, S., Guillou‐Guillemette, H. L., Boursier, J., Lunel, F., Jeannin, P., Pivert, A., & Ducancelle, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-14285-9 · Cited by 6
Gu, J., Zhang, X., Wang, Z., Cui, R., Zhang, J., Jia, Y., Miao, R., Fan, H., Wang, H., Li, Y., et al. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.07.008 · Cited by 6
Total bile acid to platelet ratio
Jiang, M., Yan, X., Song, X., Yan, Q., Zhao, Y., Wang, L., & Gao, P. (2020) · Medicine · doi:10.1097/md.0000000000020502 · Cited by 6
Bhattacharjee, J., Beaton, G., Ravula, S. B., Lee, S. J., Bacon, K. B., Jenkinson, C. P., Warren, M., Tucci, F. C., & Kohli, R. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000323 · Cited by 5
Platelet-Derived Growth Factor C in Alcoholics.
Martín-González, C., González-Navarrete, L., Ribot-Hernández, I., Vera-Delgado, V., Alvisa-Negrín, J., Godoy-Reyes, A., Espelosín-Ortega, E., Abreu-González, P., & González-Reimers, E. (2020) · Alcohol and Alcoholism · doi:10.1093/alcalc/agz094 · Cited by 5
Deng, H., Ye, H., Xiao, H. P., You, Y., Miao, X., Zhang, W., Leng, Y., Zheng, R., Shuai, X., Ren, J., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500196 · Cited by 4
Prevention of Liver Fibrosis and Hepatocellular Carcinoma Using Antiplatelet Drugs
Wang, R.-J., Wang, J., Zhang, X., Yue, Y., Shen, B., & Zhang, Y. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002219 · Cited by 4
Ghadir, M. R., Sarkeshikian, S. S., Hormati, A., Alemi, F., Alavinejad, P., Jameshorani, M., Molaei, M., & Jahangiri, M. (2019) · Hepatitis Monthly · doi:10.5812/hepatmon.92342 · Cited by 4
Daily high-dose aspirin does not lower APRI in the Aspirin-Myocardial Infarction Study
Tiwari‐Heckler, S., Jiang, Z. G., Popov, Y. V., & Mukamal, K. J. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.33.20190041 · Cited by 4
Self-citationYang, J., Wang, Y., Zhuo, L., Lu, G.-J., Zhang, M., Huang, J., Li, Y., Liu, W., Qi, J., Zhu, A., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18081228 · Cited by 3
Cho, E. H., Kim, J. A., Park, M., Kwon, M., Park, H., & Woo, H. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318847 · Cited by 3
PDGF-Mediated Regulation of Liver Fibrosis
Dobie, R., Connelly, J. C., & Henderson, N. C. (2015) · Current Pathobiology Reports · doi:10.1007/s40139-015-0096-9 · Cited by 3
Noninvasive Biomarkers for Liver Fibrosis
Shiha, G. E.-S., & Mousa, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-24432-3_36 · Cited by 3
Antiplatelet Drugs on the Recurrence of Hepatocellular Carcinoma after Liver Transplantation
Choi, M. C., Min, E., Lee, J. G., Joo, D. J., Kim, M. S., & Kim, D. G. (2022) · Cancers · doi:10.3390/cancers14215329 · Cited by 3
Platelet-Driven Routes to Chaos in a Model of Hepatitis
Nelson, M. R., Gibbins, J. M., & Dunster, J. L. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2023.113338 · Cited by 3
Does haemophilia slow down the development of liver fibrosis?
van Dievoet, M., Leclercq, I. A., Hermans, C. R. J. R., Lambert, C., Horsmans, Y., Jacquemin, M. G., & Eeckhoudt, S. (2018) · Haemophilia · doi:10.1111/hae.13630 · Cited by 3
The Use of Antifibrotic Recombinant nAG Protein in a Rat Liver Fibrosis Model
Arafah, M., Al-Qattan, M. M., Abdulmaged-Ahmed, D. A., Al-Nafesah, G. A., Jadu, N. Y., Bagayawa, R. S., Shier, M. K., Marzouk, A., & Almalki, H. S. (2019) · BioMed Research International · doi:10.1155/2019/9846919 · Cited by 3
Letter: increased platelet activation in chronic liver disease – hit two targets with a single shot
Çelikbilek, M. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13582 · Cited by 3
Chen, R., Huang, E., Wu, X., McMullen, M. R., Wang, X., Nagy, L. E., Jin, G., Cameron, S. J., & McIntyre, T. M. (2025) · The FASEB Journal · doi:10.1096/fj.202501902r · Cited by 4
Klinkhammer, B. M., Buhl, E. M., Caspers, T., Maryam, S., Wong, D. W. L., Goedertier, M., Hölscher, D. L., Bülow, R. D., Kramann, R., Hayat, S., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.01.029 · Cited by 2
Ahmed, S. A. A., Gad, S. E. M., Eida, O. M., & Lm, M. (2023) · Acta Parasitologica · doi:10.1007/s11686-023-00730-w · Cited by 2
Fan, R., Li, Y., & Du, Z. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1503090 · Cited by 2
Bhat, A., Chaudhary, S., Yadav, G., prasar, A., Bihari, C., Maras, J. S., & Sarin, S. K. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.03.186015 · Cited by 2
Ahn, J., Hur, M. H., Shin, H., Park, M. K., Won, S., Park, J., Ko, Y., Park, Y., Lee, Y. B., Cho, E. J., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0528 · Cited by 1
Self-citationHBV pgRNA induces chronic inflammation in an IL-1β-dependent manner
Skeva, A., Marmanis, K., Ntinopoulou, M., Liakopoulos, P., Tryfonopoulou, E., Chalkidou, A., Arelaki, S., Chlichlia, K., Koffa, M., Chrysanthopoulou, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1812831 · Cited by 1
Maiorca, F., Sabetta, A., Sangineto, M., Pallucci, D., Dufies, O., Poli, V., Gioia, M. D., D’Amico, T., Miglionico, M., Lombardi, L., et al. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.126.325001 · Cited by 1
Effect of aspirin use on survival in patients with hepatocellular carcinoma
Aktan, H., Özdemir, A. A., & Karaoğullarından, Ü. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002601 · Cited by 1
Inflammatory Markers Involved in the Pathogenesis of Dupuytren's Contracture
Cates, W. T., Denbeigh, J. M., Salvagno, R. T., Kakar, S., van Wijnen, A. J., & Eaton, C. (2024) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2024052889 · Cited by 2
Stokkeland, K., Söderberg, K. C., Villner, P., & Franck, J. (2025) · Liver international communications. · doi:10.1002/lci2.70011 · Cited by 1
From fatty liver to nonalcoholic steatohepatitis with fibrosis
Muriel, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99764-5.00013-5 · Cited by 1
Friedman, S. L. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch10 · Cited by 1
Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis
Schierwagen, R., Uschner, F. E., Klein, S., & Trebicka, J. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0321-y
Vetter, D., & Friedman, S. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-34062-5.00007-8
Ogbu, I. R., Akhondi, H. A., Ayutyanont, N., & Manov, A. E. (2021) · Endocrinology and Disorders · doi:10.31579/2640-1045/071
Li, W., Zhang, B., Zhu, J., Liu, J., Wang, Q., Jiang, F., & Xing, T. (2023) · medRxiv · doi:10.1101/2023.03.27.23287717
Increased platelets aggregation in liver tissue of nonalcoholic fatty liver diseasePreprint
Fan, R., & Yandong, L. I. (2024) · Research Square · doi:10.21203/rs.3.rs-3824405/v1
Analysis of the mechanisms of aspirin in cancer treatment
Zhao, X. (2024) · MATEC Web of Conferences · doi:10.1051/matecconf/202440404007
The association of chronic pain, painkiller use, and potential mediators with liver fat content
Cheng, Y., Yang, R., Yu, J., Zhou, Y., Yao, Y., Shen, C., Li, D., Zeng, R., Wan, Z., Zhao, Q., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-89496-x
Lambooij, J. M., Chavanelle, V., Vallier, M., van der Zande, H. J. P., Otero, Y. F., Otto, F., Schuurman, R., Joubioux, F. L., Maugard, T., Giera, M. A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6285712/v1
Arvind, A., & Simon, T. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-90225-3_6
FKBP9 enhances IGF2BP1-mediated m6A recognition to promote hepatocellular carcinoma progression
Yang, F., Si, A., Chi, C., Ma, W., Gu, Y., Pan, Y., Zhu, J., He, Y., Tang, X., Yu, Q., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101584
Yu, Y., Chen, Y., & Luo, Y. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04499-2
Daio, T., Kawashita, Y., Hirayama, S., Tateishi, M., Ueda, T., Yamaguchi, J., Haraguchi, M., Umeda, K., Nakamura, M., Harada, S., et al. (2026) · Cureus · doi:10.7759/cureus.100951
Zhou, J., Xu, A., Miao, J., Xu, R.-B., Zhang, Z.-M., Fan, Y.-L., Yu, J.-M., Yu, J.-J., Yuan, H.-Y., Li, P.-P., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.08.021
Chen, Z., Li, H., Ji, Q., Gao, R., Zhang, W., Wu, W., Pan, Z., Ma, H., Wang, C., You, H., et al. (2026) · Liver International · doi:10.1111/liv.70848
Platelet-derived S100A9 contributes to endotheliopathy in alcohol-associated hepatitis
Kirlin, F., Fattahi, N., García-Milian, R., Collin, F., Wang, W., Kim, Y., Lucien, F., Sun, Z., Lam, T. T., Hwa, J., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.201114
Self-citationAgouba, S. M., Bradáčová, P., Mikler, J., Drotárová, M., Belakova, K. M., Brunclíková, M., Gemelova, V. V., Staško, J., Škorňová, I., & Šimurda, T. (2026) · TH Open · doi:10.1055/a-2927-9053
Metadata
- Authors
- Yoshida, S., Ikenaga, N., Liu, S. B., Peng, Z.-W., Chung, J., Sverdlov, D. Y., Miyamoto, M., Kim, Y. O., Ogawa, S., Arch, R. H., Schuppan, D., & Popov, Y.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Pfizer (United States) (US)
- Corresponding author
- Popov, Yury
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 147
- Issue
- 6
- Pages
- 1378-1392
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2121815683
- Cited by
- 164
- References
- 36
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 13 · 2023: 15 · 2022: 18 · 2021: 15 · 2020: 17 · 2019: 14 · 2018: 5 · 2017: 21 · 2016: 10 · 2015: 8 · 2014: 1
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Tokyo Women's Medical University
- Takeda Pharmaceuticals International
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- platelet-derived growth factor beta, hepatic stellate cell activation, biliary fibrosis, liver fibrosis, platelets, low-dose aspirin, platelet depletion, CD41, alpha-smooth muscle actin, collagen deposition, fibrosis biomarkers
- MeSH terms
- ATP-Binding Cassette Sub-Family B Member 4, Adult, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Aspirin, Blood Platelets, Disease Models, Animal, Female, Humans, Liver Cirrhosis, Male, Mice, Inbred C57BL, Middle Aged, Platelet Aggregation Inhibitors, RNA, Messenger, Bile Ducts, Extrahepatic, Mice, Knockout, ATP Binding Cassette Transporter, Subfamily B, Proto-Oncogene Proteins c-sis, Hepatic Stellate Cells, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
